Annai Systems Appoints Francisco M. De La Vega as Chief Scientific Officer
Distinguished industry scientist brings significant bioinformatics and genomics expertise to data management pioneer
CARLSBAD, CA – March 4, 2014 – Annai Systems Inc., a genomic data management solution provider, today announced that Francisco M. De La Vega, D. Sc., a leading expert in the analysis and applications of high-throughput sequencing, has been appointed to the newly created role of Chief Scientific Officer.
“We are pleased to have a scientist of Francisco’s caliber become part of the Annai team,” said Michael Penley, Annai Systems’ Chief Executive Officer. “His breadth of experience and commercial track record will prove invaluable to our continued growth and delivery of world class genomic data management solutions.”
Francisco was previously Vice President of Genome Science at Real Time Genomics, a data analysis solutions provider. He also spent thirteen years at Applied Biosystems (currently Thermo Fisher), where he was most recently the Distinguished Scientific Fellow and Vice President of Next-Generation Sequencing Applications. During his tenure at AB, he oversaw the research, development, and validation of numerous innovative genetic analysis technologies and bioinformatics tools enabling high-throughput biology. Francisco received the Bio-IT World Best Practices Award in Basic Research in 2008 for a collaborative project with the Christian Albrechts University of Kiel leading to the identification of a novel Crohn’s disease gene. He has been an active participant of trend setting community projects such as the 1000 Genomes Project, where he was member of both the steering committee and analysis group, and the Genome-in-a-Bottle consortium, where he serves on the steering committee. Francisco earned his Doctor of Science degree in Genetics and Molecular Biology at the Center for Research and Advanced Studies of the National Polytechnic Institute of Mexico. Francisco has been Visiting Instructor at the Department of Genetics of the Stanford School of Medicine where he performed research in population and clinical genomics.
Dr. De La Vega commented, “Given the current state and future direction of genomic-based medicine and the role that sequencing is playing in this exciting evolution, data analysis and management are key enabling capabilities to unlock the full potential of this data. Annai Systems’ data management software and related services as well as their engagement with the cancer research community, places them in a strong position to continue to address many of the challenges that must be overcome in order to advance the field.”
About Annai Systems
Annai Systems is a leading genomic data analysis company committed to developing cost-reducing innovations the accelerate scientific discovery, maximize statistical power, and optimize data control. From data compression and storage to secondary and tertiary analysis, Annai Systems offers a true end-to-end solution designed to handle the complex needs of next-generation sequencing data in the clinical, pharmaceutical and research environments. The company’s flagship product, STARPlatform, enables researchers to innovate, collaborate, and make new discoveries – all in less time and at lower costs than traditional solutions. For more about Annai Systems, visit www.annaisystems.com.